Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Termination of Persistent Atrial Fibrillation by Catheter Ablation
- Conditions
- Atrial Fibrillation
- Interventions
- Procedure: Catheter ablation
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04958928
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Phase 2
Recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04895930
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04882345
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 232
- Registration Number
- NCT04870190
To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04814056
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
Phase 1
Completed
- Conditions
- Locally Advanced Solid TumorNon-Small Cell Lung Cancer With EGFR MutationMetastatic CancerAdenocarcinoma of Lung
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04770688
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
ENB-guided Ablation Therapy Combined With VATS in the Treatment of MPLC
Recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04730453
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
The Efficacy and Safety of TBCB vs TBFB in Diagnosis of GGO
Not Applicable
- Conditions
- Lung Ground-Glass Opacity
- Interventions
- Procedure: Transbronchial CryobiopsyProcedure: Transbronchial Forceps Biopsy
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 184
- Registration Number
- NCT04727190
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
Phase 2
- Conditions
- SCLCAnlotinib
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT04684017
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
- Conditions
- Lung Cancer
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT04636047
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath